Matuzumab
Based on 1 Customer Validation
Matuzumab (EMD 72000) is a humanized anti-EGFR monoclonal antibody that blocks EGFR activation and downstream signaling, inhibits tumor growth. Deglycosylation and the possible elimination of ADCC activity can reduce the in vivo anti-tumor activity of Mattuzumab.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.50%
- No. CAS: 339186-68-4
- Peso molecular:145.5 kDa
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-P9905
CetuximabEGFR Inhibitor -
HY-P99849
DepatuxizumabMonoclonal Antibody -
HY-P99041
PanitumumabAnti-EGFR Monoclonal Antibody -
HY-P99155
ZalutumumabEGFR Antibody -
HY-P9964
NecitumumabEGFR IgG Monoclonal -
HY-P99295
ImgatuzumabAnti-EGFR Antibody -
HY-P9968
NimotuzumabEGFR Antibody -
HY-P99306
ModotuximabAnti-Human EGFR Antibody -
HY-P9977
AmivantamabEGFR-MET Dual Antibody -
HY-P99045
SacituzumabAnti-TROP-2 Antibody -
HY-P99029
MagrolimabAnti-CD47 Antibody -
HY-P99041A
Panitumumab (anti-EGFR)Anti-EGFR Monoclonal Antibody
Ver todos los productos específicos de isoformas EGFR
More
Actividad biológica
Descripciòn
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
ERBB1/EGFR/HER1
In Vitro
Matuzumab (10 ng, 4-72 h) can exert a powerful anti-tumor ADCC effect in the target monolayer cells of head and neck squamous cell carcinoma (SCCHN)[2].
Matuzumab was enzymatically de-glycosylated to eliminate its ADCC activity, but the de-glycosylated antibody maintained its ability to bind to A431 tumor cells, block EGFR signaling, and inhibit growth in vitro[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:UM-SCC 14C, UDSCC 4, MCF-7, UM-SCC 11B and 22B
-
Concentration:10 ng
-
Incubation Time:4, 24 or 72 h
-
Result:The increase of effector:target ratios caused enhanced tumour cell killing.
Led to a significant enhancement of effector cell activity and increased ADCC.
In Vivo
Matuzumab achieves complete remission in 87% of lung cancer xenografts and 83% of gastric cancer xenografts. The growth of drug-resistant pancreatic cancer xenograft tumors decreases by 31%[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Ensayo clínico
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 nd
Aplicación
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized Human EGFR Protein (ECD, His Tag) can bind Matuzumab. The EC50 for this effect is 1.802 ng/mL. -
Flow Cytometry analysis of A431 cells labelling ERBB1/EGFR/HER1 (red) with Matuzumab (anti-ERBB1/EGFR/HER1) (HY-P9969). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.
Chemical Information
-
No. CAS 339186-68-4
-
Appearance Liquid
-
Peso molecular 145.5 kDa
-
Color Colorless to light yellow
-
SMILES
[Matuzumab]
-
Synonyms
EMD 72000
-
Envío
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
-
Ficha de datos (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Referencias
[1]. Joan H Schiller. Developments in epidermal growth factor receptor-targeting therapy for solid tumors: focus on matuzumab (EMD 72000). Cancer Invest. 2008 Feb;26(1):81-95. [Content Brief]
[2]. Bier H, et al. Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck. Cancer Immunol Immunother. 1998 May;46(3):167-73. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Matuzumab Related Classifications
HY-P9969 Related Classifications
Powered by Bioz